The most commonly used treatment for anti-erythropoietin (EPO) antibodies-mediated pure blood cell cancer (PRCA) includes cyclosporine (CyA) and prednisolone (PSL) 0.5-1.0 mg/kg. However, many patients suffering from chronic kidney diseases (CKD) as well as chronic heart disease are not able to take this immunosuppressive treatment.
A managed 86 suffering from anemia due to CKD as well as chronic heart failure who was treated with recombinant erythropoietin in a subcutaneous injection, developed anti-antibody-mediated PRCA. You can know more about Anti-Erythropoietin EPO Antibody online.
Patients were treated by CyA which was followed by PSL (1.0 mg/kg) but the patient was not able to tolerate this regimen of drugs. The PSL dosage was decreased down to 0.2 mg/kg. It was surprising to note that his reticulocyte count grew 3 months after the procedure and RBC transfusions were no longer needed. The low dose PSL is a possible treatment for patients suffering from anti-EPO antibody-mediated PRCA who are not able to take CyA as well as PSL (0.5-1.0 mg/kg).
Patients who are receiving antiviral treatment in the treatment of chronic liver disease C frequently develop anemia due to interferon and ribavirin. Recombinant erythropoietin is utilized to treat anemia that is associated with antiviral treatment and to limit dose reductions that are associated with lower rates of sustained virologic responses.
For patients suffering from chronic kidney disease with this type of condition, it has been reported that there are positive results associated with renal transplantation and the subsequent immunosuppression. In this instance, one person suffering from chronic liver diseases developed anti-erythropoietin-related purified red cells aplasia, and recovered following the transplantation of his liver and also immunosuppression.